当前位置: X-MOL 学术Trends Biochem. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Is β-Catenin a Druggable Target for Cancer Therapy?
Trends in Biochemical Sciences ( IF 11.6 ) Pub Date : 2018-07-02 , DOI: 10.1016/j.tibs.2018.06.003
Can Cui , Xianglian Zhou , Weidong Zhang , Yi Qu , Xisong Ke

Mutations of canonical Wnt signaling pathway genes frequently occur in cancer and lead to abnormal accumulation of the key effector β-catenin. Over the past decades, a number of Wnt inhibitors have been identified through high-throughput screenings, however, very few of them target β-catenin directly, raising questions regarding its druggability. Here, we review Wnt inhibitors with a focus on small molecules that directly bind β-catenin, discuss the druggability of β-catenin, and why it has rarely been targeted, especially in the cellular context. We also propose strategies to develop small molecule binding and depleting cellular β-catenin, which are generally applicable to other difficult-to-drug or yet-to-be-drugged targets.



中文翻译:

β-连环蛋白是癌症治疗的可治疗靶标吗?

典型的Wnt信号通路基因的突变在癌症中经常发生,并导致关键效应子β-catenin异常积聚。在过去的几十年中,通过高通量筛选已鉴定出多种Wnt抑制剂,但是,只有极少数的Wnt抑制剂直接靶向β-catenin,这引发了有关其可药物性的问题。在这里,我们综述了Wnt抑制剂,重点研究了直接结合β-catenin的小分子,讨论了β-catenin的可药用性,以及为什么它很少被靶向,尤其是在细胞环境中。我们还提出了发展小分子结合和消耗细胞β-catenin的策略,这些策略通常适用于其他难以毒品或尚未毒品的目标。

更新日期:2018-07-02
down
wechat
bug